VOQUEZNA (vonoprazan) - (pHalcon-EoE-201)

April 30, 2026: Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q1 2026 results and provided a business update highlighting commercial progress for VOQUEZNA (vonoprazan) and an EoE development catalyst. Net revenues were $58.3 million (+104% YoY) on ~268,000 total VOQUEZNA prescriptions in Q1 (+115% YoY); ~1.35 million total prescriptions had been filled as of April 17, 2026. Covered prescriptions grew 91% YoY, with ~63% of Q1 prescriptions covered by insurance. Operating expenses were $61.8 million (non-GAAP $56.2 million), with net cash usage of approximately $15 million; Q1 net loss was $30.4 million (non-GAAP adjusted net loss $14.7 million). Cash and cash equivalents were $180.9 million as of March 31, 2026.

Clinical catalyst: The Phase 2 pHalcon-EoE-201 trial of VOQUEZNA in eosinophilic esophagitis is enrolling ahead of schedule; topline results are now anticipated in late Q4 2026 or early Q1 2027.

Guidance: The company maintained FY 2026 guidance (net revenues $320–$345 million) and expects operating profitability (excluding stock-based compensation) beginning in Q3 2026 and for full-year 2026.